SARS-CoV-2 Antiviral Therapy
- 28 July 2021
- journal article
- review article
- Published by American Society for Microbiology in Clinical Microbiology Reviews
- Vol. 34 (4), e0010921
- https://doi.org/10.1128/cmr.00109-21
Abstract
The development of effective antiviral therapy for COVID-19 is critical for those awaiting vaccination, as well as for those who do not respond robustly to vaccination. This review summarizes 1 year of progress in the race to develop antiviral therapies for COVID-19, including research spanning preclinical and clinical drug development efforts, with an emphasis on antiviral compounds that are in clinical development or that are high priorities for clinical development. The review is divided into sections on compounds that inhibit SARS-CoV-2 enzymes, including its polymerase and proteases; compounds that inhibit virus entry, including monoclonal antibodies; interferons; and repurposed drugs that inhibit host processes required for SARS-CoV-2 replication. The review concludes with a summary of the lessons to be learned from SARS-CoV-2 drug development efforts and the challenges to continued progress.Keywords
This publication has 307 references indexed in Scilit:
- Coronaviruses Lacking Exoribonuclease Activity Are Susceptible to Lethal Mutagenesis: Evidence for Proofreading and Potential TherapeuticsPLoS Pathogens, 2013
- Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirinScientific Reports, 2013
- Broad-Spectrum Antivirals against 3C or 3C-Like Proteases of Picornaviruses, Noroviruses, and CoronavirusesJournal of Virology, 2012
- Simultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus EntryJournal of Virology, 2012
- Inhibition of SARS Pseudovirus Cell Entry by Lactoferrin Binding to Heparan Sulfate ProteoglycansPLOS ONE, 2011
- Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse modelAntiviral Research, 2011
- Exacerbated Innate Host Response to SARS-CoV in Aged Non-Human PrimatesPLoS Pathogens, 2010
- A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivoVirology, 2009
- SARS: Systematic Review of Treatment EffectsPLoS Medicine, 2006
- In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquineBiochemical and Biophysical Research Communications, 2004